Regulatory Status AOD-9604 is not FDA-approved for any medical use and is listed by the FDA as a bulk drug substance that may present safety risks. Clinical development was halted after Phase IIb trials failed to meet efficacy endpoints. Summary AOD-9604 is a synthetic analog of the HGH 177191 fragment developed for fat-metabolism research
Pharmaceutical-grade peptides from reputable suppliers undergo testing for purity, sterility, and accurate concentration
Unlike systemic fat burners, which often lead to overstimulation of the nervous system, AOD-9604 acts at the cellular level, sending a signal directly to adipocytes (fat cells) ordering them to release stored fatty acids
Beyond sequence, epigenetic evidence points to an NNMT-linked signature in human adipose tissue, indicating the pathway is dynamically active in human fat biology, not only in laboratory animals
Avoid administration during or immediately after intense exercise
By integrating Lipotropic injections into a holistic health program, you're not only aiming for temporary changes but striving for a lifelong commitment to wellness